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Abstract The cellular lifetime includes stages such as differ-
entiation, proliferation, division, senescence and apoptosis.
These stages are driven by a strictly ordered process of tran-
scription dynamics. Molecular disruption to RNA polymerase
assembly, chromatin remodelling and transcription factor
binding through to RNA edit ing, splicing, post-
transcriptional regulation and ribosome scanning can result
in significant costs arising from genome instability. Cancer
development is one example of when such disruption takes
place. RNA silencing is a term used to describe the effects of
post-transcriptional gene silencing mediated by a diverse set
of small RNA molecules. Small RNAs are crucial for regulat-
ing gene expression and microguarding genome integrity.
RNA silencing studies predominantly focus on small RNAs
such as microRNAs, short-interfering RNAs and piwi-
interacting RNAs. We describe an emerging renewal of inter-
est in a ‘larger’ small RNA, the transfer RNA (tRNA).
Precisely generated tRNA-derived small RNAs, named
tRNA halves (tiRNAs) and tRNA fragments (tRFs), have
been reported to be abundant with dysregulation associated
with cancer. Transfection of tiRNAs inhibits protein transla-
tion by displacing eukaryotic initiation factors from messen-
ger RNA (mRNA) and inaugurating stress granule formation.
Knockdown of an overexpressed tRF inhibits cancer cell
proliferation. Recovery of lacking tRFs prevents cancer me-
tastasis. The dual oncogenic and tumour-suppressive role is
typical of functional small RNAs.We review recent reports on
tiRNA and tRF discovery and biogenesis, identification and
analysis from next-generation sequencing data and a mecha-
nistic animal study to demonstrate their physiological role in
cancer biology. We propose tRNA-derived small RNA-
mediated RNA silencing is an innate defence mechanism to
prevent oncogenic translation. We expect that cancer cells are
percipient to their ablated control of transcription and attempt
to prevent loss of genome control through RNA silencing.
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Introduction
Transcription is a core step in the regulation of gene expres-
sion. It is of fundamental importance in maintaining organism
function and integrity. The transcription process involves a
number of active and intricate molecular interactions. The
inherent transcription machinery and associated cofactors are
dynamically recruited to their target DNA loci in order to
produce messenger RNA (mRNA) transcripts, actively ex-
pressing a gene. Interactions between DNA-binding factors
and chromatin play a key role in RNA polymerase assembly,
initiation, and elongation [12]. The short lasting contact be-
tween transcription factors and DNA is superimposed by in-
termittent chromatin remodelling and binding events [12].
This cyclical and loci-selective nature not only is a central
property of the transcription machinery but also has emerged
as an important modulator of physiological processes such as
differentiation, proliferation, and apoptosis.
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Perturbation of these molecular synergies can result in signif-
icant fitness costs arising from genome instability. These costs
may lead to accelerated ageing and disease. Neoplasia is a gen-
eral term used to describe the effects of uncontrolled cellular
division. These division effects may be corrected by immune
responses or medical intervention. Malignant neoplasia, or can-
cer, is associatedwith abnormal, immature, and uncontrolled cell
growth with a potential to spread to other parts of the body.
Cancer typically evades immune responses and drastic curative
measures are critical. Such measures include systemic chemo-
therapies and wide resection surgery. There are over two hun-
dred cell types in the human body, most with their own distinc-
tive pathways of homeostasis. Abhorrent cell division may arise
from a variety of biological errors.Many cancer types are caused
by somatic mutations to the genomic DNA molecule. Single
nucleotide polymorphisms can cause DNA sequence variation.
This may be beneficial in terms of organism or species evolu-
tion. It may also introduce deleterious effects. For instance, the
open reading frame of transcription may be altered and protein
production is disordered. Concerning the ~350 of our ~20,000
genes implicated in cancer development, DNA sequence varia-
tion may be lethal [31]. On a larger cytogenetic scale, chromo-
some structural variation is a normal part of human genome
variation. Complex reshuffling of the genome may be harmful
in the form of chromothripsis-related tumours and cancers
formed as a result of fusion gene translocations [5, 28, 32].
The advent of DNA microarrays and next-generation se-
quencing, creating a post-genomic era of cancer genome pro-
jects, has been instrumental in delineating molecular subtypes
of cancer.Many subtypes are associatedwith discrete biological
infrastructures leading to varied disease progression and treat-
ment responses [27]. The same technology used to decipher the
molecular heterogeneity of cancer can be used to evaluate can-
cer transcriptome data, gaining greater biological insight [27].
Rather than focusing on and attempting to rectify the drivers of
tumourigenesis, an alternative approach may be to refresh our
understanding of cancer by studying and aiding innate molec-
ular defence mechanisms. Defective coding from a transformed
genome could be corrected by non-coding regulation.
Small RNA biology
Small RNAs are a diverse set of functional, non-coding RNA
molecules that are key regulators of gene expression through the
process of gene silencing [2, 11]. Historically, ‘small RNA’ re-
ferred to any class of non-coding RNA 50–200 nucleotides (nt)
in length. Over the last 15 years, the term is specifically used to
describe ‘smaller’ small RNAs of 19–32 nt [25]. RNA polymer-
ase II transcribes precursor molecules for most small RNAs such
as microRNAs (miRNAs) and piwi-interacting RNAs (piRNAs)
in a similar manner to that of protein coding genes. Some small
RNAs are generated from structure-specific cleavages of other
parent non-coding RNAs such as YRNAs and tRNAswhich are
transcribed by RNA polymerase III [13, 24]. Small RNA re-
search is proceeding at an astoundingly fast rate. There is ever
increasing knowledge of the functions of the various classes of
small RNA as well as the pathways they operate to alter gene
regulation [11].
There is great interest in small RNAs because of their role in
modifying gene expression through RNA-mediated gene silenc-
ing mechanisms [9]. RNA silencing is a term used for small
RNA-mediated post-transcriptional gene silencing [11]. The in-
creasing variety of eukaryotic processes that small RNAs are
found to be involved in extends to transgenerational inheritance
and epigenetic memory [26]. The most prominent and well-
studied class of eukaryotic small RNA is the miRNAs which
are best known for silencing and fine-tuning the expression of
mRNAs as part of the RNA-induced silencing complex (RISC)
(Fig. 1). RISCuses themiRNAsequence to target complementary
mRNA sequences in order to physically obstruct translation.
Matching between the miRNA and mRNA can take place at the
miRNA seed sequence (nucleotides 2–8), the non-seed sequence
(nucleotides 8+), or a combination of both. miRNAs are evolu-
tionarily conserved and may silence one to many hundreds of
genes [2]. It is accepted that miRNAs do not act as ‘on/off’
switches but rather continual ‘fine-tuners’ of gene expression [11].
All species have adapted to survive in the face of short-term
variation in extrinsic and intrinsic stresses, such as nutrition,
temperature, and reproduction. Bombardment from damaging
exogenous factors such as carcinogens may overwhelm stress
protection responses and accelerate cellular ageing. A recent
hypothesis suggests that this kind of genetic inflammation
could be minimised through the activity of miRNAs in a pro-
cess known as microguarding [11]. Reports show that in organ-
isms undergoing rapid change—for example during develop-
ment or in response to periodic external perturbations such as
sexual reproduction—miRNAs can switch from gene regula-
tors to molecular guards [7, 11, 17]. In this latter role, miRNAs
may buffer against abrupt fluctuations in mRNA transcription
(Fig. 2). This can be important to prevent deleterious effects of
variation of mRNA transcript abundance and minimising ge-
netic instability leading to molecular-based disorders.
Due to their major role in modifying gene expression,
miRNAs have been the focus of many cancer studies.
Molecular approaches to profile genome-wide miRNA ex-
pression, i.e., library construction and next-generation se-
quencing, identified other types of small RNA which could
not be assigned tomiRNA loci during bioinformatics analysis.
Many of the sequencing reads mapped to mRNAs, ribosomal
RNAs and transfer RNAs (tRNAs). This data was initially
dismissed as RNA degradation. On further analysis, the non-
miRNA reads were realised to be abundant with recurring
sequences, implicating the existence of novel small RNA clas-
ses. These ‘new’ small RNAs may play an important role in
RNA silencing, microguarding and cancer.
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Discovery and role of tRNA-derived small RNAs
The best studied class of these new small RNAs are tRNA
halves (tiRNAs). First described in Escherichia coli as a mech-
anism to antagonise bacteriophage infection, tiRNAs have been
reported in numerous organisms [21, 33]. The stress-activated
ribonuclease angiogenin cleaves mature tRNAs within anti-
codon loops to produce 5′ and 3′ tiRNAs [16] (Fig. 3).
Transfection of natural or synthetic 5′ tiRNAs inhibited protein
translation in bone cancer cells by displacing eukaryotic
Fig. 1 Biogenesis and mode of action of miRNAs in RNA silencing. A
miRNA gene is expressed from the genome where it undergoes
processing in the nucleus before exportation to the cytoplasm. It
undergoes further processing to create a mature ~22 nt miRNA (in red).
The miRNA binds to a multi-domain protein assembly forming a
ribonucleoprotein complex known as the RNA-induced silencing
complex (RISC). RISC uses the miRNA sequence to bind to complemen-
tary sequences in target mRNAs and physically obstruct translation.
RISC also contains an Argonaute protein which is capable of cleaving
the mRNA if there is perfect base pairing with the miRNA seed sequence.
This type of post-transcriptional gene silencing takes place for up to
two-thirds of genes in humans
Fig. 2 The basic premise of
microguarding. External signals
such as carcinogens or products
of sexual reproduction (in green)
may enter the cell through
receptors and cause genome
instability by triggering a
fluctuation of abhorrent gene
expression. In response, small
RNAs (in red) are rapidly
switched on to form a silencing
ribonucleoprotein complex
(RNP) to counteract this
deleterious, exogenously induced
transcription
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initiation factors (eiFs) 4B, 4E and 4G from the m7G cap of
mRNA [16]. These initiation factors are vital for resolving sec-
ondary structure conformations in the 5′-UTR of mRNAs dur-
ing ribosome scanning [14]. Natural and synthetic 5′ tiRNAs
have also been reported to induce the phospho-eiF2α-
independent assembly of stress granules [16]. Stress granules
are cytoplasmic RNA multimeric bodies that form under stress
and are known to inhibit protein translation [1]. In most report-
ed cases, formation of stress granules is associated with cell
recovery, survival and cancer cell resistance to chemotherapeu-
tics [1]. The finding that angiogenin contributes to stress-
induced translational suppression suggests that tiRNAs help
to reprogram protein translation during times of cellular stress
[16, 36].
Distinct but related to tiRNAs are the less well studied
tRNA fragments (tRFs). Libraries of 17–26 nt small RNAs
were constructed from prostate adenocarcinoma cells prior to
next-generation sequencing. A significant number of se-
quences were derived from the precise processing of 5′ and
3′ ends of mature or precursor tRNAs [20]. These differ to
tiRNAs in that they are generated independent of angiogenin
and are not cleaved within the anti-codon loop. These se-
quences were classified into tRF-5s, tRF-3s and those that
map to the 3′ trailer fragment of precursor tRNAs (tRF-1 s)
[20] (Fig. 3). To demonstrate the biological relevance of tRFs,
the study investigated tRF-1001 which is derived from the 3′
end of a Ser-TGA tRNA precursor transcript that is not
retained in the mature tRNASer molecule [20]. Knockdown
of tRF-1001 impaired normal cell proliferation with a distinct
accumulation of cells in the G2 phase of the cell cycle [20].
Reduced proliferation arising from increased cell density or
serum depletion was rescued by co-introduction of a synthetic
2′-O-methyl tRF-1001 oligonucleotide [20]. The tRF-1001
molecule was reported to be generated in the cytoplasm by
tRNA 3′ endonuclease ElaC ribonuclease Z 2 (ELAC2), a
known prostate cancer susceptibility protein, suggesting an
oncogenic role for tRF-1001 [20].
Later, tRF-5s and tRF-3s were observed to behave similar-
ly to miRNAs in human cell lines. The tRFs had associations
with Argonaute proteins, and one tRF was shown to be pro-
duced by Dicer, the enzyme responsible for cytoplasmic
miRNA processing [4, 15]. The latter study further demon-
strated tRF-1s preferentially associated with Argonaute 3 and
4 [15]. It is known that miRNAs interact with all four
Argonaute proteins [6]. The deliberate sorting of different
types of small RNA, despite miRNAs and tRFs having almost
identical properties, indicates an exclusive role for tRFs in cell
biology.
Fig. 3 Schematic of tRNA-derived small RNA biogenesis from a mature
tRNAGly molecule. The stress-activated ribonuclease Angiogenin cleaves
the mature tRNA in the anticodon loop to produce two tRNA halves or
tiRNAs. The production of tRF-3s is derived from a cleavage in the 3′ T
arm loop (as the arrow indicates). The production of tRF-5s is derived
from a cleavage in the 5′ D arm loop (as the arrow indicates). Conflicting
reports show these cleavages to be Dicer-dependent and Dicer-indepen-
dent. It is theorised that an RNase generates the majority of tRF-3s and
tRF-5s instead of Dicer. In the nucleus, RNase Z produces tRF-1s from
the trailer sequence of a precursor tRNA (not shown)
Pflugers Arch - Eur J Physiol
Meta-analysis of tRF biology
Since the discovery of tRFs, there have been several studies in
a variety of model organisms. These studies conflict on the
biogenesis of tRF-5s and tRFs-3s with some implicating Dicer
and others reporting Dicer-independent pathways [22].
Several studies have shown that tRF-5s or tRF-3s can associ-
ate with Argonaute proteins and perform RNA silencing [3,
23, 35]. Other studies argue that tRF-5s cannot perform RNA
silencing, instead functioning in a similar manner to that of 5′
tiRNAs in protein translation inhibition [30].
To address the contentions on tRF biogenesis and function,
Kumar et al. took advantage of the deposited small RNA data
to perform a meta-analysis of tRFs and provide an inference to
their biology [18]. The investigation looked at 50 small RNA
datasets and concluded that tRFs are precisely generated frag-
ments and are not produced by the miRNA biogenesis path-
way [18]. Though some tRFs were discovered to be produced
by Dicer, it is more likely that other RNase enzymes (such as
RNase P and RNase Z) are responsible for the majority of tRF
generation [18]. Human photoactivatable-ribonucleoside-
enhanced crosslinking and immunoprecipitation (PAR-
CLIP) data showed a preference for tRF-5s and tRF-3s to
associate with Argonaute 1, 3 and 4 rather than Argonaute 2
[18]. Analysis of positional T to C mutational frequency indi-
cated that tRFs associate to Argonaute proteins in a similar
fashion to that of miRNAs. The reverse complements of ca-
nonical seed sequences matched crosslink-centred regions,
suggesting that tRF-5s and tRF-3s interact with thousands of
different RNAs in the cell [18]. The meta-analysis concludes
that tRFs are an abundant class of small RNAwhose biogen-
esis is distinct from miRNAs, but they have similar properties
and may play a major role in RNA silencing [18].
Despite the fact that tRFs are more evolutionarily con-
served than miRNAs, tRFs are present in similar abundance
to miRNAs and display Argonaute sorting in humans, there
was not a global repository for tRF sequences. This lack of
consensus resulted in multiple labs working on the same tRF
without realising, for example, cand45 in Cole et al. [4] is the
samemolecule as tRF-1001 in Lee et al. [20]. Moreover, a tRF
may be misannotated as a miRNA [29]. To address this issue,
Kumar et al. created a database of tRFs known as tRFdb avail-
able at www.genome.bioch.virginia.edu/trfdb/ [19].
tRFs prevent cancer metastasis
It was proposed that tiRNAs and tRFs could have roles in
cancer progression, similar to the role of miRNAs. As hypoxia
is a major stress encountered by cancer cells, tRNA-derived
small RNAs induced under hypoxic conditions may act to curb
metastatic progression [10]. This theory fits in line with
Fig. 4 Oncogenic genes are expressed by the cancer cell which promote
its survival and metastasis. YBX1 is an RNA-binding protein which
stabilises the oncogenic transcripts for translation, resulting in more
metastasis (left-hand side). The cancer cell increases production of
tRNA-derived small RNAs, which compete for YBX1 binding.
Oncogenic transcripts are destabilised (in red), and translation is
diminished, resulting in less metastasis (right-hand side). This innate
system is open to manipulation through the use of RNA mimics and
inhibitors
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microguarding concepts where cancer cells may be intuitive to
their ablated control of transcription and attempt to prevent loss
of genome control through RNA silencing [11]. Vice versa, it
may be a mechanism for a cancer cell to produce stress gran-
ules, inhibit protein translation, and reactivate when the micro-
environment is more suitable to tumour formation and growth.
A group of tRFs were identified by small RNA sequencing
that were upregulated under hypoxia in breast cancer cells as
well as non-transformed mammary epithelial cells [10].
Highly metastatic breast cancer cells did not display induction
of the same tRFs under hypoxia, suggesting a role specific to
cancer progression [10]. The study identified a common se-
quence motif present in the hypoxia-induced fragments, sug-
gesting that they interact with a common trans-factor. Using
tRFGlu as ‘bait’, the RNA-binding protein Y box binding pro-
tein 1 (YBX1) was immunoprecipitated and identified as the
trans-factor [10]. The mRNA stabilising activity of YBX1 is
suppressed by tRFs.
YBX1 is a malleable RNA-binding protein with a variety
of networking partners. It is involved in key cellular pathways
and inactivation leads to embryonic lethality [34]. YBX1 is
also overexpressed in multiple cancer types. By combining
molecular, biochemical and computational approaches, it
was reported that tRFs bind to YBX1 and displace a number
of oncogenic transcripts from YBX1 [10]. Antagonising
YBX1 activity interferes with its role in stabilising the expres-
sion of oncogenic mRNAs (Fig. 4). The displacement of these
oncogenic transcripts by tRFs suppresses their stability and
expression, therefore suppressing metastatic progression [10].
To demonstrate the physiological significance of the
hypoxia-induced tRF-YBX1 pathway, the study further used
a reporter to drive the expression of luciferase under a hypoxia
response promoter in mice xenografted with human breast
cancer. A lentiviral system with a luciferase reporter fused to
3′-UTRs of cluster of differentiation 97 (CD97) and TIMP
metallopeptidase inhibitor 3 (TIMP3), two important tRF-
YBX1 targets, was used to show lower luciferase activity in
YBX1 knockdowns post-injection [10]. The lack of luciferase
activity from reporters fused with CD97 and TIMP3 is direct
evidence of tRF-mediated displacement of oncogenic tran-
scripts from YBX1 [10].
Summary and conclusions
Transfer RNA-derived small RNAs are amongst a diverse set
of small RNAmolecules present in bacteria to humans. These
tiRNAs and tRFs can be freely generated from the tran-
scriptome or produced by stress-induced cleavages. Non-
stress-induced tRNA-derived small RNAs are thought to arise
from ribonucleolytic processing of tRNAs by Dicer and
RNase Z [4, 20]. The production of stress-induced tRNA-de-
rived small RNAs has been shown to occur via the action of
other ribonucleases such as angiogenin [8]. Multiple classes of
tiRNAs and tRFs have been identified in various cell types and
organisms. These classes are defined by the position of the tRNA
cleavage site that gives rise to the small RNAs. These include 5′
and 3′ tRNA halves that are cleaved within the anti-codon loop
[20]. These classes also include tRF-5s, tRF-3s and tRF-1swhich
are cleaved within the tRNA arm loops or trailer sequence [18].
Stress-induced tiRNAs have been reported to mediate a stress
response which results in stress granule assembly and inhibition
of protein synthesis. Additionally, tRFs can impact on a number
of cellular functions including proliferation and mediating RNA
inactivation through Argonaute co-operation.
We propose that tRNA-derived small RNAs are an innate
tumour suppressive mechanism which is open to molecular
manipulation through the use of RNA mimicry and antago-
nism. Some reports conflict with this idea where some tRNA-
derived small RNAs promote cancer. This dual role as onco-
genic and tumour suppressive is typical of functional small
RNAs. It may also be evidence of the tumour evolutionary
arms race for metastatic clonal selection. We previously sug-
gested that miRNAs can buffer against potential oncogenic
transcription [11]. Research is needed to identify other small
RNAs or mechanisms that might have a more significant role
in microguarding [11]. The costs of defective microguarding
were expected to result in accelerated ageing and increased
disposition to disease. In this review, we shift focus away from
miRNAs and discuss the role of tRNA-derived small RNAs in
preventing protein translation and in displacement of YBX1.
This added component to the microguarding phenomena of
small RNA-induced prevention of oncogenic transcription
and translation is a further exciting avenue for future research.
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